Peter F. Arkosy

Nagyerdei St. 98
Debrecen, HB 4032, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Journal: NPJ breast cancer

Published: December 15, 2025

G protein subtype preference dictates paroxetine-enhanced serotonin receptor response in non-malignant breast epithelial cells.

G protein subtype preference dictates paroxetine-enhanced serotonin receptor response in non-malignant breast epithelial cells.

Journal: Biochemical pharmacology

Published: July 24, 2025

Immunotherapy of esophageal, GEJ and gastric tumors

Immunotherapy of esophageal, GEJ and gastric tumors

Journal: Magyar onkologia

Published: June 30, 2025

Prognostic Potential of Apoptosis-Related Biomarker Expression in Triple-Negative Breast Cancers.

Prognostic Potential of Apoptosis-Related Biomarker Expression in Triple-Negative Breast Cancers.

Journal: International journal of molecular sciences

Published: May 23, 2025

Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.

Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.

Journal: Clinical and translational science

Published: April 29, 2025

Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis.

Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis.

Journal: Biomolecules

Published: March 26, 2025

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 07, 2023

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience.

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience.

Journal: Frontiers in oncology

Published: July 03, 2023

A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.

A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.

Journal: Pathology oncology research : POR

Published: June 23, 2023

Beyond a decade: a comparative study of 15-year survival rates in screen-detected vs. symptomatic breast cancer patients in Hungary.

Beyond a decade: a comparative study of 15-year survival rates in screen-detected vs. symptomatic breast cancer patients in Hungary.

Journal: Irish journal of medical science

Published: June 06, 2023

In Vivo Assessments of Mesoblastic Nephroma (Ne/De) and Myelomonoblastic Leukaemia (My1/De) Tumour Development in Hypercholesterolemia Rat Models.

In Vivo Assessments of Mesoblastic Nephroma (Ne/De) and Myelomonoblastic Leukaemia (My1/De) Tumour Development in Hypercholesterolemia Rat Models.

Journal: International journal of molecular sciences

Published: September 13, 2022

Title Not Found

Title Not Found

Journal: Magyar onkologia

Published: February 04, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026